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Purpose: To evaluate the therapeutic effects of atelocollagen absorbable punctal plugs.
Method: Seventy-four eyes in 37 patients with dry eye disease (DED) underwent punctal plug 
occlusion using atelocollagen plugs and were followed up for 24 weeks. Subjective symptoms 
were evaluated using the ocular surface disease index (OSDI) questionnaire. Ocular surface 
disease parameters, including the Schirmer test, phenol red thread test, tear break-up time 
(TBUT), and fluorescein and Rose Bengal staining, were recorded before and 1, 4, 8, 16, and 
24 weeks after treatment.
Results: In comparison with the pretreatment data, the subjective symptoms and ocular surface 
disease parameters showed significant improvement after atelocollagen punctal occlusion. The 
average time of relapse was 17.4 ± 5.1 weeks. No severe complications occurred, and none of 
the plugs had to be removed because of local discomfort or epiphora.
Conclusion: Atelocollagen absorbable punctal plugs effectively improved ocular surface 
disorders in DED. These plugs are a safe and effective alternative in the treatment of DED.
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Introduction
A variety of pharmacologic and non-pharmacologic approaches exist for the 
management of dry eye disease (DED). Treatment is typically selected based on clinical 
signs and symptoms. Artificial tears are the mainstay of treatment and can be combined 
with hyaluronate sodium, autologous serum eye drops, and/or lacrimal outflow 
occlusion. In cases where local treatment does not ameliorate the condition, punctal 
plugs have been recognized as an effective, safe, and simple treatment.1–3 There are two 
main types of punctal plugs: nonabsorbable and absorbable. Nonabsorbable plugs have 
been used widely in the treatment of dry eye disease,2–4 however complications, such as 
spontaneous loss or epiphora (tear outflow), formation of granulomas, intracanalicular 
migration, and infections have been reported.2–5
In this study, we present the clinical results of a new absorbable punctual plug made 
of atelocollagen (Keeptear; Koken Bioscience Institutes, Tokyo, Japan). Atelocollagen 
is a collagen solution that is extracted from animal dermal tissue, from which antigenic 
telopeptides attached to both ends of the collagen molecule are eliminated by pepsin 
treatment. At temperatures of 4°C or under, atelocollagen dissolves in a neutral 
phosphate buffer solution. When heated to a temperature of 37°C, the atelocollagen 
begins to solidify and turns into a white-colored gel that can be picked up using 
forceps. The plug therefore solidifies due to body temperature after injection through 
the punctum.3,6,7
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A PubMed search revealed that long-term follow-up data 
for atelocollagen absorbable punctal plugs has not yet been 
reported. Here, we report the follow-up data obtained during 
a 24-week evaluation of the therapeutic occlusion of lacrimal 
ducts using absorbable atelocollagen punctal plugs.
Materials and methods
The subjects were 74 eyes of 37 patients (34 women, 3 men; 
mean age ± standard deviation (SD), 60.5 ± 13.8 years) 
diagnosed with dry eye disease (DED) at the Yokohama City 
University Medical Center from April 2009 to March 2010. 
The diagnosis of dry eye was based on the diagnostic criteria 
of the Dry Eye Research group in Japan. In brief, dry eye was 
diagnosed in patients who had (1) dry eye-related symptoms, 
(2) positive staining with fluorescein or Rose Bengal, and 
(3) Schirmer test results of less than 5 mm, or tear break-up 
time (TBUT) of less than 5 seconds. None of the patients 
had a history of ocular surgery within 6 months prior to 
the study. None of the patients had previously undergone 
punctal occlusion. All patients gave informed consent before 
participation. This research protocol adhered to the tenets of 
the Declaration of Helsinki.
The patients had been previously treated with eye drops 
with unsatisfactory improvement in signs and symptoms. 
Prior to atelocollagen punctal occlusion, the patients had 
been using 0.1% sodium hyaluronate eye drops (Santen 
Pharmaceuticals, Osaka, Japan) and/or preservative-free 
artificial tears (Santen Pharmaceuticals). Two patients were 
using autologous serum tears and two patients were using 
0.02% fluorometholone eye drops (Santen Pharmaceuticals). 
The patients were allowed to continue concomitant treatment 
with such eye drops during the study but were asked not to 
use any further eye drops without consulting the physician. 
Systemic drugs influencing tear production were prohibited 
during the study period. The patient backgrounds were 
Sjögren’s syndrome (SS) (seven cases), post-laser in situ 
keratomileusis (LASIK) (two cases), and soft contact lens 
users (two cases). The treatment effects were evaluated using 
the Schirmer test (without local analgesia), the phenol red 
thread test, the tear break-up time (TBUT), and fluorescein 
and Rose Bengal staining. Fluorescein and Rose Bengal have 
traditionally been the dyes used for evaluation of the ocular 
surface. Fluorescein stains areas where the epithelium is 
absent, while Rose Bengal stains areas where the integrity 
of the mucin layer has been compromised.8 Fluorescein and 
Rose Bengal staining was graded from 0 to 3 at the nasal 
conjunctiva, temporal conjunctiva, and cornea, and the sum 
of the three grades was considered as the score for each eye. 
Subjective symptoms were evaluated using the ocular s  urface 
disease index (OSDI) questionnaire.9 The OSDI is a v  alidated, 
12-item questionnaire used to assess the subjective symptoms 
of ocular surface disease.
Patients were examined before and 1, 4, 8, 16, and 24 weeks 
after treatment. All complications, defined as acute infection 
of the lacrimal drainage system, granulomatous f  ormation, 
canalicular stenosis, or plug removal by the physician because 
of epiphora or local discomfort, were recorded.
Atelocollagen used in this study was extracted from 
bovine epidermis, sterilized, and packed in a sterile tube by 
Koken Bioscience Institutes (Tokyo, Japan). With patients 
laying down in a supine position, a 27-gauge blunt needle 
attached to a sterile tube containing 0.2% atelocollagen 
solution was inserted 2–3 mm into a punctum, and 
atelocollagen solution was injected into the canaliculi by 
pushing a plunger and slowly retracting the needle to fill 
the canaliculus with atelocollagen. After insertion of the 
atelocollagen punctal plug, patients were asked to keep 
their eyes closed for approximately 15 minutes. The eyes 
were warmed with a disposable eye-warming mask during 
this time to hasten solidification of the atelocollagen, 
preventing any leakage from the lacrimal ducts during 
blinking.
Statistical comparisons of the mean values between 
groups were performed using the Mann–Whitney U test. 
The treatment outcome was analyzed using the Wilcoxon 
test. A probability value ,0.05 was considered statistically 
significant.
Results
Seventy-four eyes in 37 patients underwent atelocollagen 
absorbable punctal plug treatment.
The frequency of eye drop use after treatment decreased 
in 28 patients and stayed the same in nine patients when 
compared with pretreatment frequency. No patients required 
the addition of further new eye drops after the punctal plug 
procedure.
Before treatment, mean tear secretion measured by the 
Schirmer test was 3.89 ± 0.47 mm. Schirmer test values 
significantly increased to 6.30 ± 0.33 mm at 1 week, 
5.86 ± 0.34 mm at 4 weeks, and 5.97 ± 0.47 mm at 8 weeks 
after treatment (P , 0.05) (Figure 1).
Mean tear volume measured by the phenol red thread 
test was 13.3 ± 0.85 mm before treatment. Mean tear 
  volume significantly increased to 22.9 ± 1.10 mm at 1 week, 
20.4 ± 1.13 mm at 4 weeks, and 19.5 ± 1.05 mm at 8 weeks 
after treatment (P , 0.05) (Figure 1).
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Mean TBUT was 3.65 ± 0.18 seconds before treatment. 
Mean TBUT values increased after treatment, and were 
  significantly higher at all time-points compared to pretreat-
ment values (P , 0.05) (Figure 2).
Average fluorescein staining score was 2.62 ± 0.20 before 
treatment and decreased after treatment (Figure 3). All post-
treatment values were significantly improved compared to 
pretreatment values (P , 0.05).
Average Rose Bengal staining score was 1.55 ± 0.181 
before treatment and decreased after treatment (Figure 3). All 
post-treatment values were significantly improved compared 
to pretreatment values (P , 0.05).
The mean OSDI value decreased from 55.58 ± 0.88 
before treatment and was significantly improved at all time-
points (P , 0.05). These findings suggest that the absorbable 
atelocollagen punctal plugs had a beneficial effect on the 
subjective symptoms (Figure 4).
In comparison with the pretreatment data, the subjec-
tive symptoms and ocular surface disease parameters 
(TBUT, fluorescein and Rose Bengal staining score) were 
significantly improved during the 24-week follow-up period. 
The improvement in tear volume measured with the Schirmer 
test and phenol red thread test was maintained for up to 
8 weeks after treatment. These outcomes suggest that the 
absorbable atelocollagen punctal plugs had beneficial effects 
on both the objective and subjective symptoms.
None of the patients developed any severe adverse 
events related to the procedures, and none of the plugs had 
to be removed. Two patients complained of temporary local 
discomfort which was alleviated with the use of artificial 
tears.
Twenty-four eyes were reinjected with atelocollagen 
because of deteriorating symptoms during the follow-up 
period. The average time to relapse was 17.4 ± 5.1 weeks. 
The breakdown is; two eyes: 8 weeks, one eye: 12 weeks, 
seven eyes: 16 weeks, three eyes: 20 weeks, and four 
eyes: 24 weeks. No significant differences in the objective 
pretreatment parameters (tear volume, TBUT, fluorescein and 
Rose Bengal score) were observed between the retreatment 
group and the non-retreatment group.
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Figure 1 Schirmer and phenol red thread test results after treatment. Compared with the pretreatment levels, tear volumes measured using the Schirmer test (without 
analgesia) and the phenol-red thread test significantly increased at 1 week after treatment and slightly decreased thereafter. 
Note: *P , 0.0001 according to the Wilcoxon test.
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Figure 2 Tear break-up time (TBUT) after treatment. Compared with the pretreatment level, the mean TBUT time increased after treatment. 
Note: *P , 0.0001 according to the Wilcoxon test.
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Figure 3 Fluorescein and Rose Bengal score after treatment. Compared with the pretreatment level, the fluorescein and Rose Bengal score decreased after treatment. 
Note: *P , 0.0001 according to the Wilcoxon test.
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Discussion
We investigated the therapeutic effect and complications 
associated with absorbable atelocollagen punctal plugs. Vital 
staining with fluorescein and Rose Bengal, TBUT and OSDI 
were all significantly improved during the 24-week period. 
The frequency of eye drop instillation was decreased in 28 
of the 37 patients (76%). No complications were observed 
suggesting that these plugs are safe and effective in the treat-
ment of dry eye disease.
Improvement in Schirmer test and phenol red thread test 
values maintained significance up to 8 weeks but was not 
statistically significantly different after 16 weeks. The aver-
age time to relapse in reinjection cases was 17.4 ± 5.1 weeks. 
These findings suggest that the mean duration of efficacy of 
atelocollagen punctal plugs may be around 16 weeks.
Punctal plugs have offered a safe and often reversible 
treatment option for DED. The plugs are typically made of 
nonabsorbable (silicone, polyethylene, polymethylmethacry-
late, and N-butyl cyanoacrylate)2,4,10 or absorbable (c  ollagen, 
gelatin, catgut, or hydroxypropyl methyl-cellulose)3,11 
materials. In recent years, the designs and models of punc-
tal plugs have been improved, reducing the incidence of 
complications.
Complications of nonabsorbable punctal plugs, include 
spontaneous loss, acute conjunctivitis associated with bio-
film formation, plug extrusion, epiphora, discomfort due to 
corneal or conjunctiva abrasion by the exposed portion of the 
plugs, and formation of granuloma. Intracanalicular migration 
may lead to canaliculitis and dacryocystitis.   Canaliculitis 
and dacryocystitis caused by punctal plug migration may 
necessitate surgical procedures such as canaliculotomy or 
dacryocystorhinostomy (DCR) in severe cases.10,12–16
In contrast, as atelocollagen plugs solidify after injection 
into the canaliculi, prior size determination is unnecessary. 
This property also allows their use in cases with large puncta 
or cases with granulation that makes the insertion of conven-
tional nonabsorbable plugs difficult. There is no risk of plug 
extrusion and the risk of granulomas and biofilm formation 
is minimal. The intracanalicular location of these plugs is 
also less likely to cause ocular surface irritation compared 
with conventional punctal plugs.3,4,10
The duration of action of absorbable punctal plugs is 
generally shorter than that of nonabsorbable punctal plugs. 
However the aforementioned advantages of atelocollagen 
plugs make it a safe and effective alternative to conven-
tional nonabsorbable plugs. These plugs may in particular 
be indicated for cases with repeated loss of plugs, large 
puncta, and granuloma making conventional plug insertion 
difficult. These plugs may also be used initially to predict 
which patients are likely to tolerate nonabsorbable plugs or 
to treat a transient worsening of DED.
Atelocollagen is extracted from bovine dermis and an 
enzymatic process removes the antigenic portions from the 
collagen molecule.6,7 Atelocollagen is obtained from the 
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Figure 4 Ocular surface disease index (OSDI) after treatment. Compared with the pretreatment level, the OSDI decreased, and the subjective symptoms improved after 
treatment. 
Note: *P , 0.0001 according to the Wilcoxon test.
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dermis of Australian bred calves under the strictest conditions 
of safety. There have been no reported cases of bovine 
spongiform encephalopathy (BSE) in Australia. Moreover 
calf dermis is known to be a tissue free from infection by 
BSE prions. The source calves are strictly monitored from 
birth up to the point that the dermis is obtained and dermis 
is obtained from calves under 6 months which is well below 
the earliest onset of BSE at 30 months. Therefore the risk of 
prion infection due to the use of atelocollagen is unlikely.
In order to further assess the efficacy of this treatment 
modality more stringently, a controlled study with sham plug 
insertion as the control group is warranted.
In conclusion, atelocollagen absorbable punctal plugs 
effectively improved ocular surface disorders in DED. These 
plugs are a safe and effective alternative in the treatment 
of DED.
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